Literature DB >> 31266669

Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems.

Juliana Coronel1, Ilona Behrendt2, Tim Bürgin3, Tibor Anderlei3, Volker Sandig4, Udo Reichl5, Yvonne Genzel2.   

Abstract

Driven by the concept of plug-and-play cell culture-based viral vaccine production using disposable bioreactors, we evaluated an orbital shaken bioreactor (OSB) for human influenza A virus production at high cell concentration. Therefore, the OSB model SB10-X was coupled to two hollow fiber-based perfusion systems, namely, tangential flow filtration (TFF) and alternating tangential flow filtration (ATF). The AGE1.CR.pIX avian suspension cells grew to 50 × 106 cells/mL in chemically defined medium, maintaining high cell viabilities with an average specific growth rate of 0.020 h-1 (doubling time = 32 h). Maximum virus titers in the range of 3.28-3.73 log10(HA units/100 µL) were achieved, corresponding to cell-specific virus yields of 1000-3500 virions/cell and productivities of 0.5-2.2 × 1012 virions/L/d. This clearly demonstrates the potential of OSB operation in perfusion mode, as results achieved in a reference OSB batch cultivation were 2.64 log10(HA units/100 µL), 1286 virions/cell and 1.4 × 1012 virions/L/d, respectively. In summary, the SB10-X bioreactor can be operated with ATF and TFF systems, which is to our knowledge the first report regarding OSB operation in perfusion mode. Moreover, the results showed that the system is a promising cultivation system for influenza A virus vaccine production. The OSB disposable bioreactor has the potential for simplifying the scale-up from shake flasks to the large-scale bioreactor, facilitating rapid responses in the event of epidemics or pandemics.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  High cell density; Hollow-fiber; Influenza A virus; Orbital shaken bioreactor; Perfusion; Viral vaccine production

Year:  2019        PMID: 31266669     DOI: 10.1016/j.vaccine.2019.06.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Application of an Inclined Settler for Cell Culture-Based Influenza A Virus Production in Perfusion Mode.

Authors:  Juliana Coronel; Gwendal Gränicher; Volker Sandig; Thomas Noll; Yvonne Genzel; Udo Reichl
Journal:  Front Bioeng Biotechnol       Date:  2020-07-02

2.  High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells.

Authors:  Yixiao Wu; Thomas Bissinger; Yvonne Genzel; Xuping Liu; Udo Reichl; Wen-Song Tan
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-30       Impact factor: 4.813

3.  The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process.

Authors:  Jianqi Nie; Yang Sun; Kai Feng; Lingling Huang; Ye Li; Zhonghu Bai
Journal:  Vaccine       Date:  2022-02-23       Impact factor: 4.169

Review 4.  Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects.

Authors:  Zhongbiao Fang; Jingting Lyu; Jianhua Li; Chaonan Li; Yuxuan Zhang; Yikai Guo; Ying Wang; Yanjun Zhang; Keda Chen
Journal:  Front Bioeng Biotechnol       Date:  2022-08-09

5.  Optimization of an adenovirus-vectored zoster vaccine production process with chemically defined medium and a perfusion system.

Authors:  Jianqi Nie; Yang Sun; He Ren; Lingling Huang; Kai Feng; Ye Li; Zhonghu Bai
Journal:  Biotechnol Lett       Date:  2022-10-01       Impact factor: 2.716

6.  Performance of an acoustic settler versus a hollow fiber-based ATF technology for influenza virus production in perfusion.

Authors:  Gwendal Gränicher; Juliana Coronel; Felix Trampler; Ingo Jordan; Yvonne Genzel; Udo Reichl
Journal:  Appl Microbiol Biotechnol       Date:  2020-04-15       Impact factor: 4.813

7.  Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production.

Authors:  Gwendal Gränicher; Felipe Tapia; Ilona Behrendt; Ingo Jordan; Yvonne Genzel; Udo Reichl
Journal:  Biotechnol J       Date:  2020-09-08       Impact factor: 5.726

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.